Expression of RUNX1 isoformsand its clinical significance in acute leukemia
10.3872/j.issn.1007-385x.2018.06.012
- VernacularTitle:RUNX1异构体在急性白血病中的表达及临床意义
- Author:
YANG Zhigang
1
,
2
,
3
,
4
;
LIU Jia
4
,
5
;
WEN Ruiting
4
,
5
;
WU Guocai
4
,
5
;
WANG Wei
4
,
5
;
ZHANG Yuming
4
,
5
Author Information
1. 1. Department of HematologyandRheumatology, AffiliatedZhanjiangCentralPeople&rsquo
2. sHospitalofGuangdongMedical University, Zhanjiang 524045, Guangdong, China
3. 2. Guangdong Medical University, Zhanjiang 524023, Guangdong, China
4. 3. Laboratory of Hematology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
5. 2. Guangdong Medical University, Zhanjiang 524023, Guangdong, China
- Publication Type:Journal Article
- Keywords:
RUNX1 isoforms;
acute leukemia;
evaluation of curative effect;
relapse；minimal residual disease（MRD）
- From:
Chinese Journal of Cancer Biotherapy
2018;25(6):620-628
- CountryChina
- Language:Chinese
-
Abstract:
Objective: : To investigate the relationship between the expression of RUNX1 isoforms and the clinical curative effect and the prognosis of acute leukemia (AL), in order to provide valuable experimental data for the individualized treatment, MRD (minimal residual disease) monitoring and prognosis prediction of AL. Methods: AL patients with primary treatment (PT, n=88) and recrudescence (RC, n=10) that treated at the Department of Hematology of Affiliated Hospital of Guangdong Medical University from April, 2012 to April, 2013 were included in this study. Real-time PCR was used to examine the mRNA expression of RUNX1 isoforms (RUNX1a and RUNX1b/c) in PT patients, RC patients and controls (non-malignant hematological disease patients).The changes in mRNA expression of RUNX1a and RUNX1b/c in patients before and after the chemotherapy were also observed. Results： ： (1)The expression levels of RUNX1a mRNAinAML andALL PT group andAML RC group was significantly higher than those of control group (P<0.05); The expression level of RUNX1a mRNAinAMLPT group was increased compared withALLPT group (P<0.05). (2) The expression levels of RUNX1a and RUNX1b/c mRNAinAML andALL patients at initial treatment were significantly higher than those after complete remission (CR) (P<0.05). (3) By comparing the expression levels of RUNX1a and RUNX1b/c mRNA at initial diagnosis, there was no significant difference between 6-month death group and survival group, CR group and NCR (non-complete remission) group after first cycle of chemotherapy, or the high leukocyte group and non-high leukocyte group (all P>0.05).The expression level of RUNX1a mRNA in AML-ETO positive group was higher than that of negative group (P<0.05). (4) The expression levels of RUNX1a and RUNX1b/c mRNA in patients with acute leukemia decreased with the increasing chemotherapy cycle, and significantly increased when had a relapse, which may even succeed the initial level.Conclusion: RUNX1a isoforms participate in the pathogenesis of acute leukemia, and isrelated to the relapse ofAML. The expression levels of RUNX1a and RUNX1b/c mRNAare related to the clinical efficacy that can be used as an indicator of curative effect, but have no significant correlation with the prognosis of the disease.Dynamic monitor of theexpression levels of RUNX1a and RUNX1b/c isomers can be used as an effective indicator of MRD monitoring after chemotherapy, which can be used to evaluate the efficacy and identify the risk of recurrence at early stage.
- Full text:20180612.pdf
